PDF(Pubmed)
Abstract：
Understanding tumor-host immune interactions and the mechanisms of lung cancer response to immunotherapy is crucial. Current preclinical models used to study this often fall short of capturing the complexities of human lung cancer and lead to inconclusive results. To bridge the gap, we introduce two new murine monoclonal lung cancer cell lines for use in immunocompetent orthotopic models. We demonstrate how our cell lines exhibit immunohistochemical protein expression (TTF-1, NapA, PD-L1) and common driver mutations (KRAS, p53, and p110α) seen in human lung adenocarcinoma patients, and how our orthotopic models respond to combination immunotherapy in vivo in a way that closely mirrors current clinical outcomes. These new lung adenocarcinoma cell lines provide an invaluable, clinically relevant platform for investigating the intricate dynamics between tumor and the immune system, and thus potentially contributes to a deeper understanding of immunotherapeutic approaches to lung cancer treatment.
摘要：
了解肿瘤-宿主免疫相互作用和肺癌对免疫治疗反应的机制至关重要。目前用于研究这一点的临床前模型通常无法捕获人类肺癌的复杂性，并导致不确定的结果。为了弥合差距，我们介绍了两种新的鼠单克隆肺癌细胞系，用于免疫活性原位模型。我们展示了我们的细胞系如何表现出免疫组织化学蛋白表达(TTF-1，NapA，PD-L1)和常见驱动突变(KRAS，p53和p110α）在人肺腺癌患者中可见，以及我们的原位模型对体内联合免疫疗法的反应如何，以密切反映当前临床结果的方式。这些新的肺腺癌细胞系提供了宝贵的，研究肿瘤和免疫系统之间复杂动态的临床相关平台，因此可能有助于更深入地了解肺癌的免疫治疗方法。
